Invitae Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVTAQ research report →
Companywww.invitae.com
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners.
- CEO
- Kenneth D. Knight
- IPO
- 2015
- Employees
- 1,700
- HQ
- San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $85.95K
- P/E
- -0.00
- P/S
- 0.01
- P/B
- 0.04
- EV/EBITDA
- -0.52
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 19.18%
- Op Margin
- -138.34%
- Net Margin
- -601.64%
- ROE
- -201.69%
- ROIC
- -37.74%
Growth & Income
- Revenue
- $487.00M · -5.68%
- Net Income
- $0 · 100.00%
- EPS
- $0.00 · 100.00%
- Op Income
- $175.45M
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $1.09
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.19
- Beta
- 2.80
- Avg Volume
- 240.29K
Get TickerSpark's AI analysis on NVTAQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NVTAQ Coverage
We haven't published any research on NVTAQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NVTAQ Report →